Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Journal of Inflammation Research|April 28, 2022
Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic ProstatitisMeng Zhang, Yi Liu, Jing Chen, et al.
Biochemical Pharmacology|July 7, 2024
Knockdown of miR-1293 attenuates lung adenocarcinoma angiogenesis via Spry4 upregulation-mediated ERK1/2 signaling inhibitionYang Lou, Bo Xu, Kan Huang, et al.
International Journal of Clinical and Experimental Pathology|December 3, 2013
A new technique for the obliterative urethral stricturesXianguo Chen, Kexiao Wang, Yuanping Ye, et al.
Cell Proliferation|December 24, 2024
CXCL10 Promotes Spinal Macrophage Recruitment via the JAK/STAT3 Pathway to Induce Pain in Experimental Autoimmune ProstatitisLei Chen, Ziqi Chen, Jia Chen, et al.
Free Radical Biology & Medicine|August 2, 2024
CXCR4 influences PUFA desaturation and oxidative stress injury in experimental prostatitis mice by activating Fads2 via PPARγYi Zhang, Rui Feng, Haolin Li, et al.
Mediators of Inflammation|May 26, 2026
IL-6 Exacerbates Experimental Autoimmune Prostatitis by Disrupting STAT5a-Mediated Treg Cell Function and Th17/Treg BalanceXianhong Liu, Xiaokang Bian, Shanchuan Han, et al.
Oncotarget|April 27, 2017
Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjectsKaiping Zhang, Xianguo Chen, Jun Zhou, et al.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|December 17, 2011
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trialsFei Liu, Xianguo Chen, Ejun Peng, et al.
Scientific Reports|August 13, 2024
NLRP3-mediated IL-1β in regulating the imbalance between Th17 and Treg in experimental autoimmune prostatitisXianhong Liu, Jing Chen, Shaoyu Yue, et al.
Biochemical Pharmacology|November 28, 2025
Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapyKailing Pan, Bo Xu, Yang Lou, et al.
Pageof 6